Biotech Values

[genisi]

Peter M. Nilsson, M.D., Ph.D. in the accompanying editorial on results from pre-specified group of patients with dyslipidemia:

In a prespecified subgroup analysis, there was a trend toward benefit of fenofibrate in patients with signs of dyslipidemia, which was defined as a triglyceride level of 204 mg per deciliter (2.30 mmol per liter) or more and an HDL cholesterol level of 34 mg per deciliter (0.88 mmol per liter) or less. This finding is of potential importance, since the ATP III guidelines define a high triglyceride level as 200 mg per deciliter (2.3 mmol per liter) or more and a low HDL cholesterol level as below 40 mg per deciliter (1.0 mmol per liter).2 Since many of the patients in this subgroup analysis did not meet these criteria, the role of fibrates for correcting dyslipidemia in high-risk patients with diabetes is still not settled.

http://content.nejm.org/cgi/content/full/NEJMe1002498?resourcetype=HWCIT